Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Janssen Biotech (Details)

v3.23.3
Licensing and Other Arrangements - Janssen Biotech (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 30, 2023
USD ($)
Aug. 31, 2019
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
item
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2022
USD ($)
Licensing and other arrangements                  
Revenue from contracts with customers     $ 225   $ 25 $ 1,350 $ 3,300    
Janssen Biotech Inc. | License Agreement                  
Licensing and other arrangements                  
Cash payment received   $ 2,500              
Maximum eligible milestone payments receivable per discovery product candidate   $ 3,000              
Percentage of royalty on worldwide net sales of each product upon commercialization   0.75%              
Number of milestones earned during the period | item       3          
Revenue from contracts with customers     200   $ 0 1,300 $ 0 $ 2,500  
Contract assets     0     0     $ 0
Contract liabilities     0     0     0
Capitalized contract costs     $ 0     $ 0     $ 0
Janssen Biotech Inc. | License Agreement | Dosing of first patient in a Phase 3 clinical trial                  
Licensing and other arrangements                  
Revenue from contracts with customers $ 500                
Janssen Biotech Inc. | License Agreement | Milestone achieved pursuant to agreement                  
Licensing and other arrangements                  
Revenue from contracts with customers       $ 600